Cheraghi Sara, Honardoost Maryam, Abdolmaleki Fereshteh, E Khamseh Mohammad
Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
Med J Islam Repub Iran. 2024 Jul 22;38:83. doi: 10.47176/mjiri.38.83. eCollection 2024.
Papillary thyroid carcinoma is the most frequent type of thyroid cancer. The BRAF mutation is associated with tumor progression. We explored the utility of the BRAF molecular testing on fine needle aspiration fixed specimens of patients with confirmed diagnoses of papillary thyroid carcinoma.
Fixed thyroid cytology slide specimens of 19 patients with Bethesda II to VI reports were used to detect BRAF mutation by pyrosequencing of extracted DNA.
BRAF mutation was detected in 25% of the specimens with Bethesda category III and IV nodules and in 73% of the nodules with Bethesda category V and VI.
BRAF mutation analysis can be performed on fixed fine needle aspiration cytology specimens. Although the frequency of the mutation is higher in specimens with higher Bethesda category scores, it could support clinical decision-making in thyroid nodules with intermediate Bethesda category scores.
乳头状甲状腺癌是最常见的甲状腺癌类型。BRAF突变与肿瘤进展相关。我们探讨了BRAF分子检测在确诊为乳头状甲状腺癌患者的细针穿刺固定标本中的应用价值。
对19例具有贝塞斯达II至VI类报告的甲状腺细胞固定涂片标本，通过对提取的DNA进行焦磷酸测序来检测BRAF突变。
在贝塞斯达III类和IV类结节的标本中，25%检测到BRAF突变；在贝塞斯达V类和VI类结节中，73%检测到BRAF突变。
BRAF突变分析可在细针穿刺固定细胞学标本上进行。虽然在贝塞斯达分类评分较高的标本中突变频率更高，但它可为贝塞斯达分类评分中等的甲状腺结节的临床决策提供支持。
